Inhibitors of PGHS-2Transactivator activity

Details Inhibitors of PGHS-2Transactivator activity Inhibitors of PGHS-2Transactivator activity

2011-04-19

2011-04-19

Robinson, Hope A (Department: 1652)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S005000, C435S007100, C435S320100

Reexamination Certificate

active

07927799

ABSTRACT:
Prostaglandin-endoperoxide H synthase (PGHS-2) converts arachidonic acid to prostaglandin H2. PGHS-2 is an inducible gene product undetectable in most normal human tissues, but abundant in cancer cells. The present invention exploits a previously undisclosed transcriptional function of PGHS-2 distinct from its well-established enzymatic role to identify potential therapeutic agents useful in treating cancer. The method comprises a DNA binding assay in which PGHS-2 protein binding to the C/EBP, CRE and NF-κB regions of the PGHS-2 promoter in the presence and absence of test compounds is evaluated to identify inhibitors of PGHS-2 transactivation activity.

REFERENCES:
patent: 1201766 (2002-05-01), None
patent: 1889057 (2009-04-01), None
patent: WO 98/37235 (1998-08-01), None
patent: WO98/37235 (1998-08-01), None
patent: WO2006/127731 (2007-11-01), None
Wu et al. (Arteriosclerosis Thrombosis and Vascular Biology, vol. 25 No. 4, pp. 679-685, 2005).
Liu et al. (Journal of Biological Chemistry, vol. 280, No. 5, pp. 3817-3823 Feb. 2005).
Cao et al. (Am. J. Physiol., vol. 284, pp. C1429-1437, 2003).
Arber et al, (1999), “Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer”, Curr. Gastroenterol Rep, 1:441-448.
Braunstein et al. (1996), “Efficient transcriptional silencing inSaccharomyces cerevisiaerequires a heterochromatin histone acetylation pattern”, Mol Cell Biol, 16:4349-4356.
Cao et al. (1998), “Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy”, J Biol Chem, 273:29615-29625.
Cao et al. (1999), “Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts”, Am J Physiol, 277:C1075-1085.
Cao et al. (2003), “Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression”, Am J Physiol Cell Physiol, 284:1429-1437.
Carey et al. (1983), “Antibodies to human squamous cell carcinoma”, Otolarygnol Head and Neck Surg, 91:482-491.
Davies (2003), “Cyclooxygenase-2 and chemoprevention of breast cancer”, J Steroid Biochem Mol Biol, 86:495-499.
Davies et al. (2002), “Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention”, Ann Onco, 113:669-678.
Deng et al. (2003), “Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay”, Analytical Biochemistry, 323(1):12-18.
Smith et al. (2000), “Cyclooxygenases: structural, cellular, and molecular biology”, Annu Rev Biochem, 69:145-182.
Subbaramaiah et al. (2002), “Cyclooxygenase-2 is overexpressed in HER-2
eu-positive breast cancer: evidence for involvement of AP-1 and PEA3”, J Biol Chem, 277:18649-18657.
Wang et al. (1998), “Interleukin-1 beta and dexamethasone regulate gene expression of prostaglandin H synthase-2 via the NF-KB pathway in human amnion derived WISH cells”, Prostaglandins Leokot Essent Fatty Acids, 59:63-69.
Wang et al. (2004), “Cyclooxygenase-2: a potential target in breast cancer”, Semin Oncol, 31(1 Suppl3):64-73.
Wu et al. (2005), “Transcriptional control of COX-2 via C/EBPbeta”, Arteriosclerosis, Thrombosis, and Vascular Biology, 25(4):679-685.
Wulfing et al. (2004), “Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy”, Eur Urol, 45:46-52.
Xiong et al. (2003), “Cyclooxygenase-2 expression and angiogenesis in colorectal cancer”, World J Gastroenterol, 9:1237-1240.
Xu et al. (1993), “Enhanced prostacyclin synthesis in endothelial cells by retovirus-mediated transfer of prostaglandin H synthase cDNA”, J Clin Invest, 91:843-1849.
Yoshimura et al. (2000), “Expression of cyclooxygenase-2 in prostate carcinoma”, Cancer, 89-589-596.
Yu et al. (2003), “Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus”, Cancer Lett, 198:193-201.
Zhu et al. (2002), “Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins”, J Biol Chem, 277:6923-6928.
Zimmermann et al. (1999), “Cyclooxygenase-2 expression in human esophageal carcinoma”, Cancer Res, 59:198-204.
Liu et al. (2005), “Cyclooxygenase-2 suppresses hyoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line”, Journal of Biological Chemistry, 280(5):3817-3823.
Luo et al. (1998), “Rb interacts with histone deacetylase to repress transcription”, Cell 92:463-473.
Marvin et al. (2000), “Subcellular localization of prostaglandin R synthase-2 in a human amnion cell line: implications for nuclear localized prostaglandin signaling pathways”, Prostaglandins Leukot Essent Fatty Acids, 62:7-11.
Meade et al. (1999), “Perioxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells”, J Biol Chem, 274:8328-8334.
Molina-Holgado, E. et al. (2000), “Induction of COX-2 and PGE(2) biosynthesis by IL-1 beta is mediated by PKC and mitogen-activated protein kinases in murine astrocytes”, Br I Pharmacol, 131:152-159.
Momand et al. (1992), “The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation”, Cell, 69:1237-1245.
Moran (2002), “Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks”, J Environ Pathol Toxicol Oncol, 21:193-201.
Morita et al. (1995), “Expression-activity profiles of cells transfected with prostaglandin endoperoxide H synthase measured by quantitative fluorescence microscopy”, Biochemistry, 34:7194-7199.
Oshima et al. (1996), “Supression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)”, Cell, 87:803-809.
Pai et al. (2002), “Prostaglandin E2 trans activates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy”, Nat Med, 8:289-293.
Pang et al. (2002), “Protein kinase C-epsilon mediates bradykinin-induced cyclooxygenase-2 expression in human airway smooth muscle cells”, Faseb J, 16:1435-1437.
Parfenova et al. (2001), “Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells”, Am J Physiol Cell Physiol, 281:C166-178.
Patel et al. (2002), Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2, J Biol Chem, 277:38915-38920.
Piazuelo et al. (2003), “COX-2 inhibition in esophagitis, Barrett's esophagus and esophageal cancer”, Curr Pharm Des, 9:2267-228024.
Potter et al. (2000), “NF-IL6 and CRE elements principally account for both basal and interleukin-1β-induced transcriptional activity of the proximal 528 bp of the PGHS-2 promoter in amnion-derived AV3 cells: evidence for involvement of C/EBPβ”, Molecular Human Reproduction, 6(9):771-778.
Robbins et al. (1993), “Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro”, J Biol Chem, 268:5097-5106.
Rollins et al. (1980), “Subcellular localization of prostaglandin-forming cyclooxygenase in Swiss mouse 3T3 fibroblasts by electron microscopic immunocytochemistry”, J Biol Chem, 255:4872-4875.
Smith et al. (1981), “Subcellular localization of prostaglandin forming enzymes using conventional and monoclonal antibodies”, Prog Lipid Res, 20:103-110.
Smith et al. (1996), “Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and 2”, J Biol Chem, 271:33157-33160.
Smith et al. (1996), &#x

Affiliated with

Also associated with

Rating

Inhibitors of PGHS-2Transactivator activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of PGHS-2Transactivator activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of PGHS-2Transactivator activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2711413